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Summary: We examined the epidemiology of HCC and other liver events in a multi-cohort collabo-
ration of HIV/HCV co-infected individuals. We observed shifts in incidence from 2001 to 2014 and 
identified age, cirrhosis, and low current CD4 cell count as risk factors. 
 
ABSTRACT 
 
Background: While liver-related deaths in HIV and hepatitis C virus (HCV) co-infected individuals 
have declined over the last decade, hepatocellular carcinoma (HCC) may have increased. We de-
scribed the epidemiology of HCC and other liver events in a multi-cohort collaboration of HIV/HCV 
co-infected individuals. 
 
Methods: We studied all HCV antibody-positive adults with HIV in the EuroSIDA Study, the South-
ern Alberta Clinic Cohort, the Canadian Co-infection Cohort, and the Swiss HIV Cohort Study from 
2001 to 2014. We calculated the incidence of HCC and other liver events (defined as liver-related 
deaths or decompensations, excluding HCC) and used Poisson regression to estimate incidence rate 
ratios. 
 
Results: Our study comprised 7,229 HIV/HCV co-infected individuals (68% male, 90% white). Dur-
ing follow-up, 72 cases of HCC and 375 other liver events occurred, yielding incidence rates of 1.6 
(95% confidence interval (CI): 1.3, 2.0) and 8.6 (95% CI: 7.8, 9.5) cases per 1,000 person-years of 
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follow-up, respectively. The rate of HCC increased 11% per calendar year (95% CI: 4%, 19%) and 
decreased 4% for other liver events (95% CI: 2%, 7%), but only the latter remained statistically sig-
nificant after adjustment for potential confounders. High age, cirrhosis, and low current CD4 cell 
count were associated with a higher incidence of both HCC and other liver events.  
 
Conclusions: In HIV/HCV co-infected individuals, the crude incidence of HCC increased from 2001 
to 2014, while other liver events declined. Individuals with cirrhosis or low current CD4 cell count are 
at highest risk of developing HCC or other liver events. 
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BACKGROUND 
As hepatitis C virus (HCV) and human immunodeficiency virus (HIV) have shared 
modes of transmission, individuals with HIV are more often infected with HCV than the general pop-
ulation [1]. HCV can cause chronic hepatic inflammation leading to liver fibrosis and cirrhosis that 
entails a risk of liver decompensation and hepatocellular carcinoma (HCC) [2]. Concomitant HIV 
infection accelerates this process [3, 4], and liver disease is one of the main causes of death in people 
with HIV [5]. Some studies indicate that the overall rate of liver-related death is declining in 
HIV/HCV co-infected individuals [6], but at the same time, national cohort studies have shown an 
increasing rate of HCC [7-9].  
We aimed to study HIV/HCV co-infected individuals in Europe and Canada and de-
scribe trends in the incidences of HCC and other liver events from 2001 to 2014 and identify risk 
factors for the development of HCC and other liver events.  
 
 
METHODS 
Study population 
We included all HIV/HCV co-infected individuals in four prospective cohorts of HIV-
positive individuals: the EuroSIDA study [10], which enrolls from 111 clinics across Europe, Israel, 
and Argentina; the Southern Alberta Clinic Cohort [11], which enrolls from Southern Alberta, Cana-
da; the Canadian Co-infection Cohort study (CTN222) [12], which enrolls HIV/HCV co-infected 
individuals from 18 centers across Canada; and the Swiss HIV Cohort Study [13]. All cohorts collect 
and update data at least every six months using standardized collection forms. 
We defined HCV co-infection as being HCV antibody-positive. Baseline was defined 
as the latest of first cohort or clinic visit; first positive HCV antibody-test; or January 1, 2001 (since 
data on non-AIDS defining cancers, including HCC, were collected prospectively from this date). 
Data from all participating cohorts were pooled together by use of the HIV Cohort Da-
ta Exchange Protocol [14]. 
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Outcomes 
We studied two separate outcomes: 1) HCC, and 2) other liver events, defined as liver 
decompensation or liver-related death. Liver decompensation was defined as hepatic encephalopathy 
(grade 3 or 4), hepatorenal syndrome, ascites, variceal bleeding, or spontaneous bacterial peritonitis. 
Liver-related death was defined as deaths caused by chronic viral hepatitis or other liver failure, ex-
cluding HCC. The diagnoses were based on pathology reports, hospital discharge summaries, or con-
sultation notes. For HCC, in the absence of the above, the diagnosis could also be based on a strong 
suspicion supported by evidence from radiological imaging or biochemical assay. All events were 
subsequently centrally reviewed. 
 
Statistical analysis 
Crude incidence rates of both HCC and other liver events were calculated by calendar 
time, grouped into two-year periods, and stratified by latest cirrhosis status and CD4 cell count, also 
testing for interaction between cirrhosis status and current CD4 cell count. When calculating inci-
dence of other liver events, individuals with a liver decompensation prior to baseline were excluded 
from follow-up (N = 179). 
Poisson generalized estimating equations assuming auto-regressive (AR1) correlation 
were used to investigate the association between various demographic, HIV, and lifestyle related 
characteristics and the incidence of HCC and other liver related events, separately. Variables signifi-
cant in the univariate regression models (P<0.1) were included in multivariate regression models. 
Sensitivity analyses were performed which excluded HCC cases with HIV/HCV/HBV co-infection or 
those with any cancer diagnosis (other than HCC) prior to end-of-follow-up.  
 All statistical tests were two sided with a type I error rate of 5%. Statistical analyses 
were performed using SAS 9.3 (Statistical Analysis Software, Cary NC, USA). 
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Predictor variables 
The following variables were analyzed: age*, sex, race (white, other/unknown), region 
(Europe East/Argentina, Europe West, Canada), HIV risk group (men who have sex with men 
(MSM), injection drug use (IDU), heterosexual, other/unknown), body mass index (BMI) category*, 
ever smoked*, ever abused alcohol*, diabetes mellitus*, hepatitis B virus (HBV) co-infection*, ever 
HBV active drugs*, ever HCV active drugs*, ever combination antiretroviral therapy (cART)*, ever 
acquired immunodeficiency syndrome (AIDS)*, detectable HIV RNA*, CD4 cell count current*, 
CD4 cell count nadir*, cirrhosis*, and calendar year of event. Asterisks indicate variables that were 
updated at each visit.  
BMI was calculated as weight in kilograms / squared height in meters and categorized 
as either underweight (BMI <20), normal weight (BMI 20-25), overweight (BMI 25-30), or obese 
(BMI > 30). Alcohol use was not uniformly collected in all cohorts, but where available, alcohol 
abuse was defined as consuming above 25 and 20 units per week for men and women, respectively. 
Diabetes mellitus was defined as having a diagnosis of insulin-dependent diabetes mellitus or taking 
diabetic medication or insulin. HBV co-infection was defined as the presence of hepatitis B surface 
antigen in serum. cART was defined as receiving at least three antiretrovirals from any class. Detect-
able HIV RNA was defined as having plasma HIV RNA above 400 copies per milliliter.  
Cirrhosis was defined using a hierarchical structure with cutoffs from earlier publica-
tions [15-17]: Liver biopsy with a METAVIR score of F4 was considered the highest level of evi-
dence, followed by FibroScan elasticity of 12.5 kPa or above, then aspartate aminotransferase-to-
platelet ratio index (APRI) of 2 or above, and then plasma hyaluronic acid level of 200 ng/ml or 
above. A patient was assumed cirrhotic from the date of measurement and onwards if the measure-
ment fulfilled at least one of the criteria mentioned above. If markers were inconsistent, the marker of 
highest evidence level decided the cirrhosis status. Individuals in whom we could not assess cirrhosis 
status were classified as “missing”. 
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RESULTS 
Baseline characteristics 
We included 7,229 individuals in our study (4,132 from the EuroSIDA Study; 2,044 
from the Swiss HIV Cohort Study; 840 from the Canadian Co-infection Cohort; 213 from the South-
ern Alberta Clinic Cohort). Table 1 shows the baseline characteristics of our study population. The 
majority were male (68%), white (90%), and primarily from Europe West (58%). Median age was 38 
(inter-quartile range (IQR): 36, 43) years. The main HIV risk group was IDU (59%), and 5% were 
HIV/HCV/HBV co-infected. 
 
Incidence rates of HCC and other liver events 
From 2001 to 2014, 72 cases of HCC (with 45,192 person-years of follow-up) and 375 
cases of other liver events (with 43,718 person-years of follow-up) occurred, resulting in overall inci-
dence rates of 1.6 (95% confidence interval (CI): 1.3, 2.0) cases of HCC per 1,000 person-years of 
follow-up and 8.6 (95% CI: 7.8, 9.5) cases of other liver events per 1,000 person-years of follow-up. 
Figure 1 shows the incidence rates of HCC and other liver events as a function of calendar years. The 
incidence of HCC increased by 11% per year (95% CI: 4%, 19%, p = 0.002), from 0.4 cases per 1,000 
person-years of follow-up in 2001-02 to 2.3 cases per 1,000 person-years of follow-up in 2013-14. In 
contrast, the incidence of other liver events decreased by 4% per year (95% CI: 2%, 7%, p = 0.002) 
from 9.9 cases per 1,000 person-years of follow-up in 2003-04 to 5.2 cases per 1,000 person-years of 
follow-up in 2013-14.  
In cirrhotics, the overall incidence rate of HCC was 7.9 (95% CI: 5.9, 10.5) cases per 
1,000 person-years of follow-up against 0.5 (95% CI: 0.3, 0.7) cases per 1,000 person-years of fol-
low-up in non-cirrhotics. For other liver events, the incidence rates were 35.9 (95% CI: 31.1, 41.4) 
and 2.4 (95% CI: 1.9, 3.0) cases per 1,000 person-years of follow-up for cirrhotics and non-cirrhotics, 
respectively.  
In both cirrhotics and non-cirrhotics, the incidence rates of both outcomes were lower 
in those with a current CD4 cell count above 350 cells/mm3 (Figure 2). In cirrhotics, the incidence 
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rate of HCC decreased from 10.9 (95% CI: 7.4, 16.1) cases per 1,000 person-years of follow-up in 
those with a CD4 cell count below 350 cells/mm3 to 6.1 (95% CI: 3.8, 9.7) cases per 1,000 person-
years of follow-up in those with a CD4 cell count above 350 cells/mm3. For other liver events, the 
effect was more drastic, as the incidence rate here went from 58.7 (95% CI: 49.2, 70.0) to 20.1 (95% 
CI: 15.5, 26.4) cases per 1,000 person-years of follow-up, respectively. There was no significant in-
teraction between cirrhosis and current CD4 cell count for any outcome (both p > 0.2), but the anal-
yses had low power. 
 
Characteristics at event 
Table 2 shows the characteristics at event in those who developed HCC or other liver 
events and at end-of-follow-up in the remaining cohort. Median age at event was 49.6 years for HCC 
versus 43.9 years for other liver events. Within two years of event, 75% of HCC cases and 70% of 
other liver events cases had cirrhosis. Only 8% of HCC cases and 6% of other liver events cases were 
HBV co-infected. 32% of HCC cases had ever received HCV active drugs versus 18% of other liver 
events cases. Almost all had ever received cART (99% of HCC cases and 91% of other liver events 
cases), but their most recent (within six months) CD4 cell counts were quite low with a median of 286 
(IQR: 201, 438) cells/mm3 in HCC cases and 242 (IQR: 110, 397) cells/mm3 in other liver event cas-
es. 
Of the 11 who developed HCC and had an HCV RNA measurement at least six months 
after completing interferon-based treatment, none had achieved a sustained virologic response (SVR). 
 
Risk factors for HCC and other liver events 
In multivariate analysis, higher age, HBV co-infection, lower current CD4 cell count, 
and cirrhosis were associated with a higher incidence of HCC (Table 3). Notably, we found no impact 
of alcohol abuse, diabetes mellitus, or detectable HIV RNA on the incidence of HCC in univariate 
analysis. 
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Later calendar years were significantly associated with a higher incidence of HCC in 
univariate analysis, but not in multivariate analysis, indicating that changes in other variables ex-
plained the increase over time. In a supplementary analysis, increases in the proportion with cirrhosis 
mostly explained the increase in HCC over time, as it was only after adjustment for cirrhosis that 
there no longer was a significant increase in HCC over time (adjusted incidence rate ratio per calendar 
year increase 1.05, 95% CI: 0.98, 1.13).  
The multivariate analysis of other liver events yielded similar risk factors (Figure 3 and 
Supplementary Table 1): higher age, lower CD4 cell count, and cirrhosis (but not HBV co-infection) 
were associated with a higher incidence of other liver events. Additionally, HIV risk group “oth-
er/unknown” compared with MSM, being underweight, and having ever smoked were also associated 
with a higher incidence of other liver events. Later calendar years were in both uni- and multivariate 
analysis associated with a lower incidence of other liver events with statistical significance. 
Excluding those with HBV co-infection or those with any other cancer diagnosis prior 
to end-of-follow-up did not change the results (data not shown). 
In a supplementary analysis of individuals with cirrhosis (Supplementary Table 2), we 
found that having a current APRI >3 (compared with current APRI between 2 and 3) was inde-
pendently associated with a higher incidence of other liver events. For HCC, the trend was similar, 
but not statistically significant. 
 
 
DISCUSSION 
We observed opposing trends in the crude incidence of HCC and other liver events in 
HIV/HCV co-infected individuals from 2001 to 2014: HCC increased from 0.4 to 2.3 cases per 1,000 
person-years of follow-up, whereas other liver events decreased from 9.9 to 5.2 cases per 1,000 per-
son-years of follow-up.  
An increase in HCC incidence has previously been shown in retrospective national 
studies of HIV/HCV co-infected individuals: in Spain, Merchante et al. [8] showed that the incidence 
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increased from 2000 to 2010 (0.2 to 1.4 cases per 1,000 person-years of follow-up), and, in the Veter-
ans Affairs Cohort in the United States, Ioannou et al. [9] found that the age-adjusted prevalence of 
HCC increased from 0.15% in 1996 to 1.06% in 2009. They link the rise in incidence with the in-
creased survival in individuals with HIV, as HCV-related development of cirrhosis and subsequent 
HCC takes several years [18]. Our results support this reasoning as changes in the proportion of indi-
viduals with cirrhosis – which increased by 8% per year (data not shown) – mostly explained the in-
crease in HCC per calendar year in multivariate analysis. 
However, while the proportion of cirrhotics and crude incidence of HCC was increas-
ing, we found that the incidence of other liver events, i.e. liver decompensations and liver-related 
deaths, decreased, even after adjustment. Other recent studies of HIV/HCV co-infected individuals, 
but not all [19], have shown similar trends [5-7, 20]. This could be explained by the increased uptake 
of cART, which has been found to lower the progression of hepatic fibrosis and disease [21, 22], im-
proved HCV treatment uptake [23], and possibly the discontinuation of older hepatotoxic antiretrovi-
rals [24]. In our multivariate analysis, having ever received cART or HCV active drugs did not affect 
the decrease of other liver events per calendar year, but an increase in current CD4 cell count did pro-
tect against other liver events, and the population had higher CD4 cell counts at end-of-follow-up. 
Improvements in HIV and HCV treatment have undoubtedly reduced the risk of liver decompensa-
tions and liver-related death in the last decade, but our data suggest that other explanatory factors are 
yet to be accounted for.  
It seems paradoxical that improvements in liver-related morbidity in HIV/HCV co-
infected patients, demonstrated by a lower incidence of other liver events, would simultaneously yield 
a higher incidence of HCC. Perhaps an improved management of liver cirrhosis and HIV treatment 
can increase the threshold for liver decompensation in the cirrhotic HIV/HCV co-infected individuals, 
but thus increasing longevity such that viral hepatocarcinogenesis has enough time to manifest itself 
as HCC. This hypothesis is somewhat supported in our finding that for cirrhotics, the decrease in inci-
dence rate was much more pronounced for other liver events than for HCC when comparing those 
with a current CD4 cell count less than 350 cells/mm3 to those with a count above 350 cells/mm3, 
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though formal analysis for interaction between cirrhosis and current CD4 cell count was not statisti-
cally significant. 
In our multivariate analysis, the major risk factor for HCC was cirrhosis. We found that 
74% of individuals with HCC had cirrhosis within six months of HCC diagnosis. As “missing” cir-
rhosis status also was associated with a higher incidence of HCC, it is likely that the markers used in 
our definition of cirrhosis have not identified all cirrhotics, rather than an actual situation in which 
26% of individuals developed HCC without cirrhosis. However, as liver biopsies are being replaced 
by the same non-invasive markers, our result warns that HCC can develop in individuals who do not 
seem to have cirrhosis based on these markers.  
We also found that lower current CD4 cell count was associated with HCC in 
HIV/HCV co-infected individuals. Previous studies have also shown this in HIV individuals in gen-
eral [9, 25, 26], but in HCV/HIV co-infected individuals, the results have been conflicting: Salmon et 
al. [27] did not find an association, arguing that any association is likely confounded by cirrhosis as 
concomitant splenic sequestration of lymphocytes artificially lowers the CD4 cell count [28]. Howev-
er, Kramer et al. [29] found that having a CD4 cell count of <200 cells/mm3 (compared with >350 
cells/mm3) was associated with a 1.7 times greater hazard of HCC, and that the association remained 
when analyzing the subgroup with cirrhosis. In our study, we found a significant protective effect of a 
doubling in current CD4 cell count after adjustment for cirrhosis, corroborating the independent effect 
of current immunosuppression as a risk factor for HCC. 
In addition to cirrhosis and CD4 cell count, HBV co-infection and higher age were in-
dependent risk factors for HCC. However, these factors (except HBV co-infection) were also risk 
factors for other liver events. The effect sizes were different, but for a singular case, the clinician 
should perceive the aforementioned risk factors as general predictors of liver disease and death, and 
not HCC exclusively, especially as the incidence of HCC, though increasing, remains low. 
Alcohol abuse and diabetes mellitus has been associated with an increased risk of HCC 
amongst HCV mono-infected individuals. Our study found no influence of a history of alcohol abuse 
on the risk of HCC (or other liver events after adjustment), but since our data on alcohol abuse were 
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heterogeneous and scarce, we cannot rule out that (continued) alcohol abuse impacts the risk of de-
veloping HCC or other liver events. Our study found no association between diabetes mellitus and 
HCC or other liver events, consistent with other studies [9, 27], although the latter study found an 
association between insulin resistance and the risk of HCC. 
Our study has several limitations: First, our diagnosis of cirrhosis was based primarily 
on non-invasive techniques. However, the measurements and their respective cutoffs have been vali-
dated [30], and possible misclassifications would underestimate any real effect of cirrhosis in our 
analyses, where it in fact was the strongest predictor. Second, we defined (chronic) HCV co-infection 
by the presence of HCV antibodies, and as around 20% can clear the infection spontaneously, we 
might have included some individuals with resolved HCV infection, which may have diluted the inci-
dence rates reported. Third, data on alcohol abuse were only recently added to some of our cohorts 
and were thus very limited. Fourth, we only had data on HCV treatment, but not treatment outcome 
(SVR rates), which likely would have been a more precise covariate to include in our regression mod-
els. The major strength of our study is that our population is taken from prospective cohorts, repre-
senting a large portion of Europe and Canada and with a relatively large proportion of females render-
ing our results readily applicable to the Caucasian population. 
In conclusion, we observed that from 2001 to 2014, the incidence of HCC in HIV/HCV 
co-infected individuals increased – largely explained by an increase in the number of individuals with 
cirrhosis – whereas the rate of other liver events (liver decompensations and liver-related deaths) de-
creased. Higher age, cirrhosis, and lower current CD4 cell count were independent risk factors for 
both HCC and other liver events. New HCV treatment with direct-acting antivirals and earlier HIV 
treatment will likely reduce the rates of HCC and other liver events, but as HCC can develop after 
achieving SVR [31], or as a consequence of long-tern alcohol abuse, non-alcoholic steatohepatitis, or 
other hepatotoxic exposures, continuous surveillance of incidence trends is needed. 
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sen, Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus, U B Dragsted, 
Roskilde Hospital, Roskilde; L N Nielsen, Hillerod Hospital, Hillerod. Estonia: (K Zilmer), West-
Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-Järve. Finland: (M 
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Ristola), I Aho, Helsinki University Central Hospital, Helsinki. France: (J-P Viard), Hôtel-Dieu, Par-
is; P-M Girard, Hospital Saint-Antoine, Paris; L Cotte, Hôpital de la Croix Rousse, Lyon; C Pradier, 
E Fontas, Hôpital de l'Archet, Nice; F Dabis, D Neau, Unité INSERM, Bordeaux, C Duvivier, Hôpital 
Necker-Enfants Malades, Paris. Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, 
Medizinische Hochschule Hannover; O Degen, University Medical Center Hamburg-Eppendorf, In-
fectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stefan, JW Goethe 
University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universi-
tät Köln, Cologne. Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology 
Research Center, Tbilisi. Greece: (J Kosmidis), P Gargalianos, G Xylomenos, P Lourida, Athens 
General Hospital; H Sambatakou, Ippokration General Hospital, Athens. Hungary: (J Szlávik), Szent 
Lásló Hospital, Budapest. Iceland: (M Gottfredsson), Landspitali University Hospital, Reykja-
vik. Ireland: (F Mulcahy), St. James's Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov 
Hospital, Tel Aviv; E Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, 
Hadassah University Hospital, Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusa-
lem. Italy: (A D’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R Es-
posito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S Maria 
Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; M Zaccarelli, A 
Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A 
Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, 
Milan. Latvia: (B Rozentale), Infectology Centre of Latvia, Riga. Lithuania: (V Uzdaviniene) Vilnius 
University Hospital Santariskiu Klinikos, Vilnius; R Matulionyte, Center of Infectious Diseases, Vil-
nius University Hospital Santariskiu Klinikos, Vilnius. Luxembourg: (T Staub), R Hemmer, Centre 
Hospitalier, Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit 
van Amsterdam, Amsterdam. Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Os-
lo. Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A Horban, E Bakow-
ska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak,  A Grzeszczuk, Medical University, 
Bialystok; M Parczewski, M Pynka, K Maciejewska, Medical Univesity, Szczecin; M Beniowski, E 
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Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; T Smiatacz, M Gensing, Medical Univer-
sity, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz; I 
Mozer-Lisewska, Poznan University of Medical Sciences, Poznan. Portugal: (M Doroana), L Caldei-
ra, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital 
Curry Cabral, Lisbon. Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. 
Victor Babes, Bucarest. Russia: (A Rakhmanova) (deceased), Medical Academy Botkin Hospital, St 
Petersburg; A Rakhmanova, St Petersburg AIDS Centre, St Peterburg; T Trofimora, Novgorod Centre 
for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E 
Kuzovatova, Nizhny Novgorod Scientific and Research Institute, Nizhny Novogrod. Serbia: (D Jev-
tovic), The Institute for Infectious and Tropical Diseases, Belgrade. Slovakia: A Shunnar, D 
Staneková, Dérer Hospital, Bratislava. Slovenia: (J Tomazic), University Clinical Centre Ljubljana, 
Ljubljana. Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S 
Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J 
Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA 
Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-
Gasteiz. Sweden:  (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital, Stock-
holm; A Blaxhult, Venhälsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, 
Malmö. Switzerland: (B Ledergerber), R Weber, University Hospital Zurich; M Cavassini, University 
Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, University Hospital Bern; M 
Battegay, University Hospital Basel; P Schmid, Cantonal Hospital St. Gallen. Ukraine: (E Kravchen-
ko), Kiev Centre for AIDS, Kiev; V Frolov, G Kutsyna, I Baskakov, Luhansk State Medical Universi-
ty, Luhansk; A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, Crimean 
Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and Con-
trol CTR, Lviv. United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospi-
tal, London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA 
Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Cam-
pus); C Orkin, Royal London Hospital, London; J Weber, G Scullard, Imperial College School of 
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Medicine at St. Mary's, London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western 
General Hospital, Edinburgh.  
The following centers have previously contributed data to EuroSIDA: Hôpital de la Pit-
ié-Salpétière, Paris, France. Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany. 1st 
I.K.A Hospital of Athens, Athens, Greece. Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, 
Italy. Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy. Ospedale Cotugno, III Divi-
sione Malattie Infettive, Napoli, Italy. Hospital Carlos III, Departamento de Enfermedades Infeccios-
as, Madrid, Spain. Odessa Region AIDS Center, Odessa, Ukraine  
EuroSIDA Steering Committee: J Gatell, B Gazzard, A Horban, I Karpov, B Lederger-
ber, M Losso, A d’Arminio Monforte, C Pedersen, A Rakhmanova, M Ristola, A Phillips, P Reiss, J 
Lundgren, J Rockstroh, S De Wit  
EuroSIDA Coordinating Centre Staff: O Kirk, L Peters, C Matthews, AH Fischer, A 
Bojesen, D Raben, D Kristensen, K Grønborg Laut, JF Larsen, D Podlekareva. Statistical Centre 
Staff: A. Mocroft, A. Phillips, A. Cozzi- Lepri, L. Shepherd, A. Schultze. 
The Canadian Co-Infection Cohort would like to acknowledge the participants of the 
Canadian Co-Infection Cohort (CTN 222) and thank Olugbenga Adebayo, Claire Allen,  Brenda 
Beckthold, Claire Casavant, Isabelle Chabot, Warmond Chan, Victor Chiang, Sarah De Coutere, 
Bruce Ganase, Laurie Gokool, Sandy Kassir, Jennifer Kocilowicz, Judy Latendre-Paquette, Nancy 
McFarland, Anja Mcneil, Jessica Milloy, Chantal Morrisseau, Mina Perez, Marie-Claude Plaisance, 
Laura Puri, Annie Qiu, for their assistance with study coordination, participant recruitment and care. 
Co-Investigators of the Canadian Co-Infection Cohort are Drs. Lisa Barrett, Jeff Cohen, Brian Con-
way, Curtis Cooper, Pierre Côté, Joseph Cox, John Gill, Shariq Haider, Mark Hull, Valerie Martel-
Laferriere, Julio Montaner, Erica Moodie, Neora Pick, Anita Rachlis, Danielle Rouleau, Aida Sadr, 
Stephen Sanche, Roger Sandre, Mark Tyndall, Marie-Louise Vachon, Sharon Walmsley, Alexander 
Wong, David Wong. 
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Table 1.  Baseline Characteristics of 7,229 HIV/Hepatitis C Virus Co-Infected Individuals 
Characteristic  
Age, years, median (IQR) 38.1 (32.6, 43.4) 
Female sex, N (%) 2,304 (31.9) 
White race, N (%) 6,530 (90.3) 
Region, N (%)  
Europe West 4,200 (58.1) 
Europe East/Argentina 1,976 (27.3) 
Canada 1,053 (14.6) 
HIV risk group, N (%)  
Men who have sex with men 834 (11.5) 
Injection drug use 4,289 (59.3) 
Heterosexual 1,188 (16.4) 
Other/unknown 918 (12.7) 
BMI category, N (%)a  
Underweight 111 (4.1) 
Normal weight 2,003 (74.5) 
Overweight 496 (18.5) 
Obese 78 (2.9) 
Ever smoked, N (%)b 2,168 (71.7) 
Ever abused alcohol, N (%)c 165 (13.3) 
Diabetes mellitus, N (%) 200 (2.8) 
HBV co-infection, N (%)d 329 (5.1) 
Ever HBV active drugs, N (%) 381 (5.3) 
Ever HCV active drugs, N (%) 735 (10.2) 
Ever cART, N (%) 5,138 (71.1) 
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Ever AIDS, N (%) 1,822 (25.2) 
Detectable HIV RNA, N (%)f 2,540 (41.6) 
CD4 cell count, cells/mm3, median (IQR)g 388 (240, 571) 
CD4 cell count nadir, cells/mm3, median (IQR)h 208 (95, 351) 
Cirrhosis, N (%)i 342 (5.9) 
Year of baselinej, N (%)   
2001-02 3,185 (44.1) 
2003-04 799 (11.1) 
2005-06 892 (12.3) 
2007+ 2,353 (32.5) 
Abbreviations: IQR, inter-quartile range; BMI, body mass index; AIDS, acquired immunodeficiency 
syndrome; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HBV, hepatitis B virus. 
a Body mass index was categorized in 2,668 individuals. 
b Smoking status was determined in 3,025 individuals. 
c Alcohol abuse was determined in 1,241 individuals.  
d HBV co-infection was determined in 6,485 individuals. 
f Detectable HIV RNA was determined in 6,099 individuals. 
g CD4 cell count was determined in 6,802 individuals. 
h CD4 cell count nadir was determined in 7,098 individuals. 
i Cirrhosis was determined in 5,799 individuals. 
j Baseline was defined as the latest of first visit; first positive HCV-antibody test; or January 1, 2001. 
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Table 2.  Characteristics of HIV/Hepatitis C Virus Co-Infected Individuals Within Six 
Months of Diagnosis of Hepatocellular Carcinoma or Other Liver Event or Within Six Months 
of End-of-Follow-Up in the Remaining Cohort 
Characteristic No HCC or other 
liver event  
(n = 6,787) 
HCC  
(n = 72) 
Other liver event  
(n = 375) 
Age, years, median (IQR) 44.8 (37.6, 50.8) 49.6 (46.0, 55.8) 43.9 (38.6, 49.6) 
Follow-up time, years, median 
(IQR) 
5.3 (2.5, 9.7) 6.0 (2.4, 9.2) 3.9 (1.6, 6.7) 
Female sex, N (%) 2,182 (32.1) 17 (23.6) 106 (28.3) 
White race, N (%) 6,124 (90.2) 68 (94.4) 343 (91.5) 
Region, N (%)    
Europe West 3,882 (57.2) 55 (76.4) 266 (70.9) 
Europe East/Argentina 1,898 (28.0) 6 (8.3) 73 (19.5) 
Canada 1,007 (14.8) 11 (15.3) 36 (9.6) 
HIV risk group, N (%)    
Men who have sex with men 802 (11.8) 6 (8.3) 27 (7.2) 
Injection drug use 4,003 (59.0) 40 (55.6) 249 (66.4) 
Heterosexual 1,129 (16.6) 17 (23.6) 43 (11.5) 
Other/unknown 853 (12.6) 9 (12.5) 56 (14.9) 
BMI category, N (%)a    
Underweight 179 (6.8) 3 (12.0) 23 (13.9) 
Normal weight 1,794 (68.6) 17 (68.0) 109 (65.7) 
Overweight 527 (20.2) 4 (16.0) 27 (16.3) 
Obese 115 (4.4) 1 (4.0) 7 (4.2) 
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Ever smoked, N (%)b 2987 (80.1) 25 (75.8) 180 (86.5) 
Ever abused alcohol, N (%)c 610 (18.6) 4 (20.0) 22 (30.6) 
Diabetes mellitus, N (%) 313 (4.6) 6 (8.3)  29 (7.7)  
HBV co-infection, N (%)d  292 (4.5) 6 (8.3) 23 (6.3) 
Ever HBV active drugs, N (%) 2,633 (38.8) 34 (47.2) 136 (36.3) 
Ever HCV active drugs, N (%) 1,537 (14.6) 23 (31.9) 68 (18.1) 
Ever cART, N (%) 5,964 (87.9) 71 (98.6) 340 (90.7) 
Ever AIDS, N (%) 2,163 (31.9) 28 (38.9)  167 (44.5)  
Detectable HIV RNA, N (%)e 1,189 (25.1) 9 (15.5) 123 (38.4) 
CD4 cell count current, 
cells/mm3, median (IQR)f 
470 (289, 670) 286 (201, 438) 242 (110, 397) 
Cirrhosis, N (%)h 1,447 (25.0) 45 (75.4) 189 (69.7) 
Abbreviations: HCC, hepatocellular carcinoma; IQR, inter-quartile range; BMI, body mass index; 
AIDS, acquired immunodeficiency syndrome; cART, combination antiretroviral therapy; HBsAg, 
hepatitis B surface antigen; HCV, hepatitis C virus; HBV, hepatitis B virus; APRI, aspartate ami-
notransferase-to-platelet ratio index. 
a Body mass index was categorized in 2,615 individuals without an event, 25 individuals with HCC, 
and 166 individuals with other liver events. 
b Smoking status was determined in 3,728 individuals without an event, 33 individuals with HCC, and 
208 individuals with other liver events. 
c Alcohol abuse was determined in 3,278 individuals without an event, 20 individuals with HCC, and 
72 individuals with other liver events.  
d HBV co-infection was determined in 6,489 individuals without an event, 69 individuals with HCC, 
and 366 individuals with other liver events. 
e Detectable HIV RNA was determined in 4,746 individuals without an event, 58 individuals with 
HCC, and 320 individuals with other liver events. 
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f CD4 cell count current was determined in 6,254 individuals without an event, 69 individuals with 
HCC, and 349 individuals with other liver events. 
g CD4 cell count nadir was recorded in 6,773 individuals without an event, all individuals with HCC 
and 370 individuals with other liver events. 
h Cirrhosis was determined in 5,799 individuals without an event, 61 individuals with HCC, and 271 
individuals with other liver events.
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Table 3.  Univariate and Multivariate Analyses of Hepatocellular Carcinoma in 
HIV/Hepatitis C Virus Co-Infected Individuals 
 Univariate analysis Multivariate analysisa 
 IRR (95% CI) p-value IRR (95% CI) p-value 
Age at baseline, per 10 year in-
crease 
2.43 (2.06, 2.88) < 0.01 2.36 (1.89, 2.94) < 0.01 
Sex, female vs. male 0.61 (0.36, 1.06) 0.08 1.01 (0.58, 1.77) 0.96 
Race, other/unknown vs. white 0.65 (0.24, 1.77) 0.40   
Region     
Europe West Reference  Reference  
Europe East/Argentina 0.32 (0.14, 0.74) 0.01 0.65 (0.28, 1.51) 0.31 
Canada 1.27 (0.6, 2.42) 0.47 0.68 (0.32, 1.45) 0.32 
HIV risk group     
Men who have sex with men Reference    
Injection drug use 1.06 (0.45, 2.50) 0.89   
Heterosexual 1.79 (0.71, 4.51) 0.22   
Other/unknown 1.07 (0.38, 3.01) 0.89   
BMI category     
Underweight 2.40 (0.70, 8.22) 0.16   
Normal weight Reference    
Overweight 0.91 (0.31, 2.71) 0.87   
Obese 1.26 (0.17, 9.39) 0.82   
Unknown 1.14 (0.65, 1.98) 0.65   
Ever smoked     
No Reference    
 at E-Library Insel on June 27, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
27 
Yes 0.84 (0.38, 1.85) 0.66   
Unknown 1.07 (0.50, 2.28) 0.87   
Ever abused alcohol     
No Reference    
Yes 1.34 (0.45, 4.01) 0.61   
Unknown 0.66 (0.38, 1.15) 0.14   
Diabetes mellitus, yes vs. no 1.95 (0.86, 4.46)  0.11   
HBV co-infection     
No Reference  Reference  
Yes 2.17 (0.94, 5.02) 0.07 2.46 (1.03, 5.87) 0.04 
Unknown 0.72 (0.23, 2.28) 0.58 0.96 (0.31, 2.96) 0.95 
Ever HBV active drugs, yes vs. no 1.92 (1.12, 3.04)  < 0.01 1.00 (0.59, 1.68) 0.99 
Ever HCV active drugs, yes vs. no 2.06 (1.26, 3.38)   < 0.01 1.27 (0.74, 2.16)  0.39 
Ever cART, yes vs. no 12.03 (1.67, 86.58)  < 0.01 5.79 (0.77, 43.69)  0.09 
Ever AIDS, yes vs. no 1.51 (0.94, 2.42) 0.09 1.20 (0.69, 2.06) 0.52 
Detectable HIV RNA     
No Reference    
Yes 0.56 (0.28, 1.14) 0.11   
Unknown 0.83 (0.46, 1.50) 0.53   
CD4 cell count current, per log2 
increase in cells/mm3 
 
0.74 (0.66, 0.83) 
 
< 0.01 
 
0.78 (0.65, 0.95) 
 
0.01 
CD4 cell count nadir, per log2 
increase in cells/mm3 
 
0.88 (0.80, 0.97) 
 
< 0.01 
 
1.07 (0.90, 1.27) 
 
0.43 
Cirrhosis     
No Reference    
Yes 17.21 (9.74, 30.41) < 0.01 12.92 (6.97, 23.95) < 0.01 
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Unknown 5.51 (2.56, 11.87) < 0.01 5.80 (2.52, 13.39) < 0.01 
Calendar year of event, per year 
increase 
 
1.11 (1.04, 1.19) 
 
< 0.01 
 
1.05 (0.98, 1.13) 
 
0.17 
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; BMI, body mass index; AIDS, ac-
quired immunodeficiency syndrome; HCV, hepatitis C virus; HBV, hepatitis B virus; cART, combi-
nation antiretroviral therapy. 
a Variables with a p-value of < 0.10 in the univariate analysis were included in the multivariate analy-
sis. 
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FIGURE LEGENDS 
 
Figure 1 Trend in Incidence Rates (with 95% Confidence Intervals) of Hepatocellular Carcino-
ma and Other Liver Events in 7,229 HIV/Hepatitis C Virus Co-Infected Individuals from 2001 to 
2014 
 
Figure 2 Incidence Rates (with 95% Confidence Intervals) for Hepatocellular Carcinoma and 
Other Liver Events in HIV/Hepatitis C Virus Co-Infected Individuals Stratified by Cirrhosis Status 
and Current CD4 Cell Count (Cells per mm3). Note: Formal Analysis of Interaction between Cirrhosis 
and Current CD4 Cell Count was Non-Significant for Both Outcomes (All P-values > 0.2) 
 
Figure 3 Adjusted Incidence Rate Ratios (with 95% Confidence Intervals) for a Selection of 
Risk Factors for Hepatocellular Carcinoma (HCC) and Other Liver Events in Multivariate Time-
Updated Poisson Regression Models 
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